European Medicines Agency announces AstraZeneca vaccine is safe; a low-dose aspirin regimen may help reduce severe COVID-19 outcomes; President Joe Biden sends excess AstraZeneca vaccines to Canada and Mexico.
On Thursday, the European Medicines Agency (EMA) announced the AstraZeneca COVID-19 Vaccine is safe after numerous countries suspended its use over fear of blood clots, The New York Times reports. A review of millions of cases concluded the vaccine does not increase the overall risk of blood clots but notes there are still uncertainties. The EMA will also add a warning label to the vaccine so medical professionals can monitor for a potential rare complication leading to blood clots and bleeding in the brain, according to The Times. However, the agency noted the vaccine will prevent more illness and death than it might cause. The announcement comes as Europe faces an increase in COVID-19 cases and continues to suffer 20,000 deaths per week from COVID-19.
A retrospective observational study published in Anesthesia & Analgesia found a low-dose aspirin treatment was associated with a lower likelihood of mechanical ventilation, intensive care unit admission, and in-hospital mortality among hospitalized patients with COVID-19, CIDRAP reports. Among the 412 hospitalized patients included in the study, those who took aspirin (of whom 75.5% were taking it before admission and 86.7% received it within 24 hours of admission) also needed significantly less oxygen support upon admission. These also patients exhibited lower initial levels of fibrinogen, a protein involved in blood clotting. Those who received the drug were more likely to have comorbidities including hypertension, diabetes, coronary artery disease, or renal disease.
President Joe Biden announced the United States will send millions of surplus doses of the AstraZeneca COVID-19 vaccine to Mexico and Canada, The Hill reports. The vaccine is currently not approved in the United States, but the country has 7 million doses ready to distribute. Distribution plans are not finalized yet but include sending 2.5 million doses to Mexico and 1.5 million doses to Canada. Press Secretary Jen Psaki also suggested the administration could share extra supplies with other countries in the future. The plan is not expected to impact the President’s mission to make vaccines available to all US adults by the end of May, according to The Hill, while Canada is expected to pay back the United States with doses later this year.
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More